Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBM588 with Nivolumab/Ipilimumab in mRCC
NCT03829111Phase 1Completed
- Sponsor
- City of Hope
- Start
- May 2019
- Primary completion
- Dec 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clostridium butyricum in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by City of Hope. Primary endpoint: Change in Bifidobacterium composition of stool at Week 12. Started May 2019; status: completed.
02
Drugs
clostridium butyricum
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03829111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829111.